GVB Biopharma Takes Control as Industry Leader in Cannabis

Business by 2FIRSTS.ai
Jan.04.2024
GVB Biopharma Takes Control as Industry Leader in Cannabis
Leading industrial hemp and cannabis industry company, GVB Biopharma, announced its return to private ownership effective December 28, 2023.

According to a report by the United States Press Agency on January 3rd, leading industrial hemp and cannabis industry enterprise GVB Biopharma announced that as of December 28, 2023, the company will be under the leadership of its founding team once again.

 

GVB Biopharma has consistently been at the forefront of the industry with its cutting-edge low-temperature cannabis extraction, refinement, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB Biopharma is committed to maintaining the reputation of its high-quality and highly regarded products. The company has successfully reverted to being a privately-owned entity, allowing it to be more flexible in adapting to the changes in the global cannabis market in the future.

 

Chief Executive Officer Drew Spiegel has expressed, "As the cannabis industry continues to mature, our vision and capabilities align perfectly with market trends. Under our commitment to quality, innovation, and esteemed clientele, we are thrilled to be at the forefront of the next phase of industry growth.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Malaysia says Japan and New Zealand’s regulated smoke-free alternatives have hastened smoking declines, whereas Thailand’s post-2014 ban drives smokers to cigarettes or the black market—evidence, PMI argues, that pairing regulated alternatives with traditional controls could improve public health faster.
Oct.15 by 2FIRSTS.ai
Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets
Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets
Philip Morris International (PMI) has partnered with Italian design brand Seletti on a limited-edition IQOS collaboration, unveiled at Milan’s Pirelli HangarBicocca. The collection features two models, launching first in Japan before rolling out to 13 global travel retail markets. PMI says the partnership leverages design and cultural storytelling to advance its smoke-free transition.
Oct.28 by 2FIRSTS.ai
2Firsts Observation|PMI Launches IQOS ILUMA i × SELETTI Limited Edition at Dubai Airport
2Firsts Observation|PMI Launches IQOS ILUMA i × SELETTI Limited Edition at Dubai Airport
2Firsts observed that Philip Morris International (PMI) has set up a large-scale IQOS display at Dubai International Airport’s duty-free area, featuring the TEREA tobacco stick series with promotional offers. The brand also showcased its limited-edition collaboration with Italian design house SELETTI — IQOS ILUMA i × SELETTI — further strengthening its premium image through artistic design.
Nov.13 by 2FIRSTS.ai
Singapore Sentences Malaysian Lorry Driver to 27 Weeks Over Cross-Border Vape Smuggling
Singapore Sentences Malaysian Lorry Driver to 27 Weeks Over Cross-Border Vape Smuggling
A 32-year-old Malaysian driver, Mohammad Fakaruddin Mohd Rosli, was sentenced to 27 weeks’ jail after pleading guilty to smuggling more than 14,000 vapes and components into Singapore and later attempting to leave the country illegally by hiding in another lorry’s cargo hold.
Nov.04 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s shisha brand Al Fakher has launched its rechargeable pod-based vape Crown Switch in Germany, featuring Coldstream technology and claiming low-temperature vaporization without ceramic or metal heating elements. The device is now available on shisha-world, while AIR is simultaneously pushing ahead with its plan to go public on Nasdaq via a SPAC merger.
Nov.20 by 2FIRSTS.ai